1. | mponesto | |
2. | dddimensions | |
3. | thegoldbug | |
4. | ladygodiva9293 | |
5. | 49bjoe |
1. | mponesto | |
2. | dddimensions | |
3. | thegoldbug | |
4. | ladygodiva9293 | |
5. | 49bjoe |
1. | dddimensions 04/25/2018 New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors |
2. | davsdu94 02/14/2018 up 11.02%. |
3. | thegoldbug 02/26/2018 Another biotech winner so far in 2018, up 50% so far. |
4. | 49bjoe 04/11/2018 Company has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and saf… |
5. | renysion 06/04/2018 Nektar Therapeutics (NKTR): Should You Cut and Run? |
6. | davsdu94 06/04/2018 Upgraded to BUY on my list ;) {Image} |
7. | einstein4539 06/07/2018 Nektar Therapeutics (NKTR): One Bull Is Still 'Impressed' Despite This Stock's Worst Plunge on Record |
8. | nomercjr 05/14/2018 Canaccord Genuity sets PT at $94 |
9. | ladygodiva9293 06/04/2018 H.C. Wainwright Slashes Price Target on Nektar Therapeutics (NKTR), Says 'Optimism Has Been Eroded' |
10. | dddimensions 04/24/2018 Nektar Therapeutics enters into a new clinical collaboration |